The pharma’s stock roared higher today after the company announced that its experimental treatment for levodopa-induced dyskinesia in patients with Parkinson’s disease met its primary endpoint in a late-stage study.
The pharma’s stock roared higher today after the company announced that its experimental treatment for levodopa-induced dyskinesia in patients with Parkinson’s disease met its primary endpoint in a late-stage study.